v3.25.1
Consolidated Statements of Changes in Shareholders' Deficit - USD ($)
Common Stock [Member]
Common Class A [Member]
Common Stock [Member]
Common Class B [Member]
Common Stock [Member]
Aspire Biopharma Inc [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Aspire Biopharma Inc [Member]
Retained Earnings [Member]
Retained Earnings [Member]
Aspire Biopharma Inc [Member]
Total
Aspire Biopharma Inc [Member]
Preferred Stock [Member]
Series A Preferred Stock [Member]
Aspire Biopharma Inc [Member]
Balance - December 31, 2023 at Dec. 31, 2022 $ 719     $ (9,938,620)   $ (9,937,901)    
Balance, shares at Dec. 31, 2022 7,187,500                
Conversion of Class B shares to Class A $ 719 $ (719)          
Conversion of Class B shares to Class A, shares 7,187,500 (7,187,500)                
Reduction of U/W Fee Payable   10,812,500     10,812,500    
Contribution - shareholder non-redemption agreement   118,298     118,298    
Shareholder non-redemption agreements   (118,298)     (118,298)    
Face value of convertible note in excess of fair value   152,430     152,430    
Remeasurement for Class A shares to redemption value     (5,813,213)   (5,813,213)    
Net (loss) gain for the period     4,464,079   4,464,079 $ (359,070)  
Balance -December 31, 2024 at Dec. 31, 2023 $ 719 $ 22,000 10,964,930 $ 957,500 (11,287,754) $ (1,467,361) (322,105) (487,861)
Balance, shares at Dec. 31, 2023 7,187,500 440,000,000            
Contribution - shareholder non-redemption agreement       784,302       784,302    
Shareholder non-redemption agreements   (784,302)     (784,302)    
Face value of convertible note in excess of fair value   315,464     315,464    
Remeasurement for Class A shares to redemption value     (548,676)   (548,676)    
Net (loss) gain for the period (12,537,472) (1,309,872) (12,537,472) (1,309,872)
Fair value of subscription loan - conversion option       (2,477,416)       (2,477,416)    
Issuance of common stock for cash          
Issuance of common stock for cash, shares                  
Issuance of preferred stock for cash       257,613     257,645 $ 32
Issuance of preferred stock for cash, shares                 322,059
Balance -December 31, 2024 at Dec. 31, 2024 $ 719 $ 22,000 $ 8,802,978 $ 1,215,113 $ (24,373,902) $ (2,777,233) $ (15,570,205) $ (1,540,088) $ 32
Balance, shares at Dec. 31, 2024 7,187,500 440,000,000             322,059